Phase II clinical trial of low-dose interleukin-2, interferon-alpha, and low-dose tegafur uracil therapy for advanced renal cell cancer.

Tomoyuki Kato, Sadafumi Kawamura, Tetsuo Fujita et al.|Journal of Clinical Oncology|2015

Cited by 0